IDEXX Laboratories, Inc. (NASDAQ:IDXX) Holdings Reduced by ING Groep NV

ING Groep NV decreased its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 32.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 11,338 shares of the company’s stock after selling 5,416 shares during the period. ING Groep NV’s holdings in IDEXX Laboratories were worth $4,688,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of IDXX. FSA Wealth Management LLC bought a new position in IDEXX Laboratories in the 3rd quarter worth about $25,000. E Fund Management Hong Kong Co. Ltd. boosted its holdings in shares of IDEXX Laboratories by 5,700.0% in the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company’s stock valued at $29,000 after acquiring an additional 57 shares in the last quarter. Retirement Wealth Solutions LLC bought a new position in shares of IDEXX Laboratories in the fourth quarter valued at approximately $31,000. Ashton Thomas Securities LLC bought a new position in shares of IDEXX Laboratories in the third quarter valued at approximately $37,000. Finally, Kestra Investment Management LLC bought a new stake in IDEXX Laboratories during the fourth quarter worth approximately $38,000. Institutional investors own 87.84% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently weighed in on IDXX shares. Bank of America raised their target price on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a report on Tuesday, February 4th. Piper Sandler upped their price target on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a research report on Monday, February 10th. Morgan Stanley reduced their price target on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating for the company in a research report on Wednesday, January 29th. Leerink Partners initiated coverage on shares of IDEXX Laboratories in a research report on Monday, December 2nd. They issued an “outperform” rating and a $500.00 price target for the company. Finally, StockNews.com downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, February 5th. Four research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $533.75.

IDEXX Laboratories Stock Down 0.0 %

IDXX stock opened at $452.77 on Friday. IDEXX Laboratories, Inc. has a 12-month low of $398.50 and a 12-month high of $583.39. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. The company has a market cap of $37.08 billion, a price-to-earnings ratio of 42.43, a PEG ratio of 3.39 and a beta of 1.37. The company has a 50 day moving average of $431.50 and a two-hundred day moving average of $452.42.

Insiders Place Their Bets

In other news, EVP George Fennell sold 9,986 shares of the firm’s stock in a transaction on Monday, February 10th. The shares were sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the transaction, the executive vice president now owns 8,176 shares in the company, valued at approximately $3,781,645.28. This trade represents a 54.98 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director M Anne Szostak sold 3,000 shares of the firm’s stock in a transaction on Friday, February 7th. The shares were sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the transaction, the director now owns 3,061 shares in the company, valued at $1,426,242.34. This represents a 49.50 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 13,330 shares of company stock worth $6,161,276 in the last quarter. 2.11% of the stock is currently owned by corporate insiders.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.